Managing potential conflict of interest in journal article publication

International Journal of Mental Health Nursing

Volumn 22, Issue 4, 2013, Pages 368-373

  O'Brien, Louise ^a   Lakeman, Richard ^b   O'Brien, Anthony ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SOUTHERN CROSS UNIVERSITY   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Conflict of interest; Mental health nursing; Pharmaceutical industry; Potential conflict of interest; Publication

Indexed keywords

ARTICLE; AUSTRALIA; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMAN; PSYCHIATRIC NURSING; PUBLICATION; PUBLISHING;

AUSTRALIA; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; PERIODICALS AS TOPIC; PSYCHIATRIC NURSING; PUBLISHING;

EID: 84879315011     PISSN: 14458330     EISSN: 14470349     Source Type: Journal    
DOI: 10.1111/j.1447-0349.2012.00869.x     Document Type: Article

References (24)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. text revision. Washington, DC: American Psychiatric Association.
2. Ashmore, R. & Carver, N. (2001). The pharmaceutical industry and mental health nursing. British Journal of Nursing (BJN), 10 (21), 1396-1402.
3. Australian Research Council (2009). ARC guidelines for disclosure of interests and confidentiality obligations. [Cited 9 May 2012]. Available from: URL: http://www.arc.gov.au/about_arc/coe_guidelines.htm#conflict
4. Cosgrove, L., Krimsky, S., Vijayaraghavan, M. & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 75 (3), 154-160.
5. Dunlevy, S. (2012). 'Campaign' targets depression guru Ian Hickie, The Australian. [Cited 9 May 2012]. Available from: URL: http://www.theaustralian.com.au/news/health-science/campaign-targets-depression-guru/story-e6frg8y6-1226269135293
6. Gray, R. & Robson, D. (2006). Concordance Skills: A Manual for Mental Health Workers. Sydney: Janssen-Cilag Pty Ltd.
7. Haines, I. E. & Olver, I. (2008). Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry? Medical Journal of Australia, 189 (5), 263-266.
8. Hickie, I. B. & Rogers, N. L. (2011). Novel melatonin-based therapies: Potential advances in the treatment of major depression. The Lancet, 378 (9791), 621-631.
9. Institute of Medicine of the National Academies (2009). Conflict of Interest in Medical Research, Education and Practice; Report Brief. Washington, WA: Institute of Medicine of the National Academies.
10. International Committee of Medical Journal Editors (2008). Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. [Cited 9 May 2012]. Available from: URL: http://www.icmje.org/
11. Jones, M., Lancashire, S., Gurney, S. & Gray, R. (2009). Eugenics by the back door? The unintended consequences of restricting people's choices about mental health medicines. Journal of Psychiatric and Mental Health Nursing, 16 (8), 758-761.
12. Jureidini, J. & Raven, M. (2012). Novel melatonin-based treatments for major depression. The Lancet, 379 (9812), 216-217.
13. Kjaergard, L. & Als-Nielsen, B. (2002). Association between competing interests and authors' conclusions: Epidemiological study of randomised clinical trials published in the BMJ. British Medical Journal, 325 (7358), 249-252.
14. Lakeman, R. (2010). Mental health nursing is not for sale: Rethinking nursing's relationship with the pharmaceutical industry. [Commentary]. Journal of Psychiatric & Mental Health Nursing, 17, 172-177.
15. Lakeman, R. & Cutcliffe, J. R. (2009). Misplaced epistemological certainty and pharmaco-centrism in mental health nursing. Journal of Psychiatric & Mental Health Nursing, 16 (2), 199-205.
16. Lexchin, J., Bero, L. A., Djulbegovic, B. & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal, 326 (7400), 1167-1170.
17. Licurse, A., Barber, E., Joffe, S. & Gross, C. (2010). The impact of disclosing financial ties in research and clinical care: A systematic review. Archives of Internal Medicine, 170 (8), 675-682.
18. de Melo-Martín, I. & Intemann, K. (2009). How do disclosure policies fail? Let us count the ways. The FASEB Journal, 23 (6), 1638-1642.
19. Resnik, D. B. (2007). The Price of Truth. How Money Affects the Norms of Science. New York: Oxford University Press.
20. Roseman, M., Milette, K., Bero, L. A. etal. (2011). Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA: The Journal of the American Medical Association, 305 (10), 1008-1017.
21. Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W. D. & Lieb, K. (2010). The financing of drug trials by pharmaceutical companies and its consequences. Part 1: A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International, 107 (16), 279-285.
22. Stahl, S. M. (2001). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press.
23. Steinbrook, R. (2009a). Controlling conflict of interest - proposals from the Institute of Medicine. New England Journal of Medicine, 360 (21), 2160-2163.
24. Steinbrook, R. (2009b). Physician-industry relations - will fewer gifts make a difference. New England Journal of Medicine, 360 (6), 557-559.